ClinicalTrials.gg
Active, not recruitingNCT06420245REBOUNDUpdated Aug 28, 2026

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

An interventional study of Orion TM Amniotic Membrane Allograft and Standard of Care (SOC) in Diabetic Foot Ulcer, sponsored by Legacy Medical Consultants. Active, not recruiting at 8 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Legacy Medical Consultants · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
38th of 322
240 · median 60
Started
2025
with 29 others
No phase
186 of 381
38 open now
Primary completion
2026-11
later than 40 of 83 live
Registered
316th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 38th largest by planned enrollment of the 322 interventional ones that give a count, is one of 30 that started in 2025, is one of 186 with no phase, reaches primary completion later than 40 of the 83 other live ones, and was the 316th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot ulcers. The study aims to determine the incidence of complete wound closure at the end of 12 weeks of treatment. Researchers will compare the outcomes between a group of people treated with standard wound care and another group treated with standard wound care in addition to the amniotic membrane allograft to see if the amniotic membrane allograft improves wound healing.

During the study, participants will visit their doctor weekly over a 12 week period, which is standard for diabetic foot ulcer treatment procedures, and fill out a questionnaire measuring quality of life.

Read the detailed description

Lower extremity diabetic ulcers are a common complication affecting millions of people in the United States. The purpose of this study is to evaluate the clinical utility of Orion™, a dual-layer amniotic membrane allograft, versus standard wound care in the management of diabetic foot ulcers. Amniotic membrane allografts are confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271 for the management of diabetic foot ulcers. Investigators hypothesize that the group of participants who receive amniotic membrane allografts in addition to standard wound care will experience a faster rate and higher incidence of complete wound closure compared to standard wound care alone. For only partially healed wounds, investigators anticipate a statistically significant reduction in the size of the ulcer and improved quality of life for participants in the experimental arm compared to standard wound care alone.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • amniotic membrane allograft
  • diabetic foot ulcer
  • DFU
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ambulatory patients ≥ 50 and ≤ 85 years of age;
  2. Willing and able to provide ;
  3. Willing and able to comply with study requirements;
  4. Presence of Wagner 1 and superficial Wagner 2 DFU extending at least through the dermis provided the DFU is located in the foot distal to the medial malleolus
  5. If multiple Wagner 1 and superficial Wagner 2 DFUs are present, the largest ulcer meeting DFU eligibility criteria will be selected as the index DFU in the study;
  6. Index ulcer is able to be visualized and accurately measured with eKare Insights;
  7. Non-study ulcers must be > 2 cm (.79 in.) from the index ulcer;
  8. Index DFU identified ≥ 4 weeks prior to study screening and \< 52 weeks from the date of informed consent;
  9. Index DFU area > 1.0 cm2 (0.39 in.) and \< 25 cm2 (9.84 in.) at screening and at Wound Management Period Visit #1;
  10. Index DFU offloaded according to SOC for entire run-in period, prior to randomization;
  11. Potential participant is under the care of a clinician for diabetic management and other medical conditions (the site PI may assist/direct the patient in the pre-screening period to obtain a PCP).
  12. Index foot has adequate circulation defined as meeting one (1) of the following within 30 days of screening:

A. ABI ≥ 0.7 and ≤ 1.3 AND TBI > 0.7; B. Dorsum transcutaneous oxygen tension measurement (TcPO2) ≥ 40 mmHg; C. Arterial duplex with biphasic flow in BOTH the DP and PT arteries verified by PI and documented.

Exclusion criteria

Exclusion Criteria

  1. Index foot ulcer documented to be caused by a medical condition other than diabetes;
  2. Potential subject has five (5) or more DFUs and/or VLUs in the target limb;
  3. DFU is secondary to Charcot neuroarthropathy;
  4. Treatment with an antibiotic impregnated primary dressing ≤ 4 weeks prior to study screening;
  5. Index ulcer is potentially or confirmed by to be cancerous;
  6. Index ulcer site has undergone radiation therapy;
  7. Venous leg ulcers in diabetic patients;
  8. Active infection proximal to or at site of index ulcer;
  9. Index foot ulcer reduced in area by ≥ 20% at the end of the 4-week run-in period;
  10. Presence of active osteomyelitis or bone infection as verified by x-ray /MRI within 30 days of visit #1 of the run-in period;
  11. Raynaud's disease;
  12. Unreconstructible arterial ischemia which may lead to nonhealing;
  13. Treatment with , including systemic for ≥ 2 weeks within 30 days prior to study screening, or are anticipated during study participation;
  14. Any active cancer undergoing treatment ≤ 30 days prior to wound management visit #1 of the run-in period, or is anticipated during study participation;
  15. Treatment with chemotherapy within 30 days of the first study wound management visit of the run-in period, or is anticipated during study participation;
  16. Diabetics with poor metabolic control, defined as ≥ 12.0%, within 30 days of visit #1 of the run-in period;
  17. Participation in an device, biologic, or drug study currently or within 30 days of study wound management visit #1 of the run-in period;
  18. Prior use of any advanced skin substitute product on the index ulcer within 60 days of visit #1 of the run-in period;
  19. Index ulcer was continued to be treated after visit #1 of the run-in period and/or anticipate treatment during study participation with any of the following prohibited therapies:

    1. Biomedical or topical growth factor;
    2. Topical steroids applied to the index ulcer surface;
    3. On medications that are considered immune system modulators that could affect graft incorporation;
    4. Scarlet red dressing;
    5. Dakin's solution;
    6. Mafenide acetate;
    7. Tincoban;
    8. Zinc sulfate;
    9. Povidone-iodine solution;
    10. Polymyxin/nystatin;
    11. Chlorhexidine;
  20. Patient is taking a cyclooxygenase-2 inhibitor (COX-2 inhibitor); such as, celecoxib (Celebrex, Consensi, Elyxyb), valdecoxib (Bextra), amlodipine (Consensi);
  21. Patient has serum creatinine > 2.5 mg/dL within 30 days of study wound management visit #1 of the run-in period;
  22. connective tissue disease;
  23. End stage renal disease (ESRD);
  24. Presence of any condition which would seriously compromise the subject's ability to complete this study;
  25. Known history of poor adherence to medical therapy and/or clinic appointments;
  26. Pregnant, or planning to become pregnant during the study;
  27. \< 1 year.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Standard of Care (SOC)

    Standard of care DFU wound management

    Procedure: Standard of Care (SOC)

  • Experimental
    Amniotic Membrane plus Standard of Care

    Weekly application of Orion™ amniotic membrane allograft in addition to standard of care DFU wound management

    Device: Orion TM Amniotic Membrane Allograft · Procedure: Standard of Care (SOC)

Interventions

  • DeviceOrion TM Amniotic Membrane Allograft

    The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.

  • ProcedureStandard of Care (SOC)

    Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.

06

What researchers measure

Primary outcomes

  1. Incidence of Complete Wound Closure

    Percentage of enrolled study participants demonstrating 100% re-epithelialization of the index wound without leaking exudate at 12 weeks post-randomization.

    Time frame: starting from randomization until last visit of the 12-week wound management period

Secondary outcomes

  1. Time to complete wound closure

    time to 100% re-epithelialization of the index ulcer without leaking exudate as assessed by Kare inSight®, starting at randomization through identification of complete wound closure.

    Time frame: From time of randomization until the end of the twelve (12) week Wound Management Period.

  2. Incidence of complete wound closure

    Incidence of complete wound closure, defined as 100% re-epithelialization of the index ulcer without leaking exudate as assessed by eKare inSight® at eight (8) weeks post-randomization.

    Time frame: From time of randomization to eight (8) weeks post-randomization.

  3. Number of Orion™ Allografts or collagen alginate (SOC) dressings required for complete wound closure.

    The number of Number of Orion™ Allografts or collagen alginate (SOC) dressings required for complete wound closure during twelve (12) week Wound Management Period.

    Time frame: From the time of randomization through the twelve (12) week Wound Management Period.

  4. Change in Quality of Life metrics

    Change in QoL metrics at twelve (12) weeks post-randomization compared to baseline as reported by the subject in the WOUND-Q QoL questionnaires: Life Impact (8-32; higher is better); Lower Limb Symptoms (10-40; higher is better)

    Time frame: starting from randomization to last visit of the 12-week wound management period

  5. Recurrence Within Six Months

    Recurrence within six (6) months post wound managment period completion, defined as meeting the primary endpoint and reopening of index ulcer at the same site within six (6) months.

    Time frame: starting from last visit of the 12-week wound management period until 6-month follow-up visit

  6. Change in wound size

    Percent area change of index ulcer at completion of twelve (12) weeks post-randomization.

    Time frame: from the time of randomization through twelve (12) weeks post-randomization.

  7. Change in QoL metrics in follow-up.

    Change in QoL metrics to six (6) months after completion of the Wound Management Period as reported by the patient in the WOUND-Q QoL questionnaire.

    Time frame: From time of completion of the Wound Management Period through six (6) months.

  8. Adverse events

    Adverse events from randomization through six (6) month follow-up.

    Time frame: From the time of randomization through six (6) month follow-up.

  9. Serious adverse events

    Occurrence of serious adverse events (SAEs) from randomization through six (6) month follow-up.

    Time frame: From the time of randomization through six (6) month follow-up.

  10. Major amputations

    Major amputations defined as amputation above the metatarsals.

    Time frame: From the time of randomization through six (6) month follow-up.

  11. Minor amputations

    Minor amputations defined as amputation involving toe or metatarsal only.

    Time frame: From the time of randomization through six (6) month follow-up.

  12. Hospital admission(s)

    Hospital admission(s) and diagnosis from randomization through six (6) month follow-up.

    Time frame: From the time of randomization through six (6) month follow-up.

  13. Emergency Department (ED) visit(s)

    ED visit(s) without admission through six (6) month follow-up.

    Time frame: From the time of randomization through six (6) month follow-up.

Other outcomes

  1. Per-Patient Product Cost

    Per-patient product cost for Orion™ Allografts during the course of wound management.

    Time frame: starting from randomization until last visit of the 12-week wound management period.

  2. Number of wound management products used.

    Number of wound management products used in each group.

    Time frame: Following completion of the 12-week Wound Management Period (WMP Visit #13) through the six (6) month follow-up.

07

Study locations

8 sites
  • DPMG
    Palm Springs, California 92262, United States
  • Center for Clinical Research Inc.
    San Francisco, California 94115, United States
  • ILD Research Center
    Vista, California 92081, United States
  • Stamford Health Medical Group
    Darien, Connecticut 06820, United States
  • Optimum Care Research Center
    Pembroke Pines, Florida 33025, United States
  • Rosalind Franklin University of Medicine and Science
    Chicago, Illinois 60064, United States
  • Chesapeake Research Group
    Pasadena, Maryland 21122, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 11 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 17, 2024
StartActual
Dec 30, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Jul 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06420245
Lead sponsor
Legacy Medical Consultants
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Dec 30, 2025
Primary completion
Nov 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion